IBMs, Dual

IBM's Dual Narrative: Can a 0.7nm Chip and a Software Comeback Coexist?

28.06.2026 - 15:49:20 | boerse-global.de

After a 60% rally, IBM stock hovers near its 200-day moving average. Nanostack chip and quantum foundry fuel AI hopes, but bears flag prototype risks. Q2 earnings on July 22 are key.

IBM Stock Rally: AI Chip Hype vs. Technical Reality – What's Next?
IBMs - IBM's Dual Narrative: Can a 0.7nm Chip and a Software Comeback Coexist? 28.06.2026 - Bild: über boerse-global.de

Few stocks have whipsawed investors as violently as IBM this spring. After tumbling to a 52-week low of €181.32 in mid-May, the shares rocketed to a year-high of €292.85 by early June — a rally of more than 60% in three weeks. The question that rattles through trading desks is simple: Is this the Mainframe relic of old, or a legitimate AI software house? The answer, it turns out, may be both.

The latest leg of the recovery has been powered by two very different forces. On the technical side, IBM clawed back above its 200-day moving average on Friday, closing at €237.80 — a premium of just 0.81% over the €235.90 threshold that long-term trend watchers treat as sacrosanct. The relative strength index sits at a neutral 55.6, leaving room to run but offering no conviction. On the fundamental side, the company unveiled its Nanostack architecture on June 25, a 0.7-nanometer chip packing 100 billion transistors on a fingernail-sized die. That announcement, paired with the launch of the Anderon quantum foundry as a standalone US subsidiary, sent the stock up nearly 10% in the following week. Yet the year-to-date performance remains a sobering minus 4.36%.

The bull case, such as it is, rests on a "software-first" thesis gaining traction among institutions. Red Hat's OpenShift platform is being counted on to deliver the growth that IBM's legacy consulting arm can no longer guarantee. First-quarter numbers bolstered the narrative: earnings per share of $1.91 beat the $1.81 consensus, and revenue climbed 9.5% to $15.92 billion. Institutions such as Welch Group and Cornerstone Wealth Group added to their positions in the first quarter. The Nanostack chip, promising up to 50% more performance or 70% lower power consumption versus current 2nm nodes — and a sixfold speed boost for AI accelerators — adds a hardware kicker that aligns with the market's insatiable hunger for energy-efficient compute.

Should investors sell immediately? Or is it worth buying IBM?

The bear case is equally well-subscribed. The 0.7nm process is still in the prototype stage; volume production is at least five years away. The fault-tolerant quantum system "Starling" is not expected until 2029. Anderon's $2 billion joint investment with the US government reduces capital risk, but if the foundry fails to attract external customers, it becomes a cost sink rather than a profit centre. Meanwhile, competitors iterating on existing nodes could nibble away at IBM's market share in the interim. Technically, the stock remains nearly 19% below its 52-week high, and the annualised 30-day volatility of roughly 70% scares off conservative money.

The immediate catalysts are macro and micro. The US jobs report, due on Thursday July 2 because of the Independence Day holiday, will influence rate expectations and, by extension, the valuation of large-cap tech. A weak print could pressure IBM's consulting revenue; a strong one would support the soft-landing thesis. More critically, July 22 brings second-quarter earnings after the bell. Analysts expect EPS of $3.01 on revenue of $17.84 billion. The real prize for investors, however, would be any concrete timeline for first external wafer sales from the Anderon foundry. That would transform a long-term promise into a tangible revenue pipeline.

For now, consensus price targets cluster in the low €258 range — sources cite both €258.07 and €257.94, implying upside of about 8.5% from Friday's close. To get there, IBM must hold above the 200-day line at €235.90; a slip beneath it would put the 50-day average at €218.00 into play as support. The RSI's neutral reading suggests the stock is unencumbered by overbought conditions, but with volatility this high, a single data point or a disappointing earnings call could unwind weeks of progress. The rally back above the 200-day is an encouraging sign. The test of whether IBM can sustain its dual identity — hardware visionary and software turnaround — begins in earnest on July 22.

Ad

IBM Stock: New Analysis - 28 June

Fresh IBM information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated IBM analysis...

en | US4592001014 | IBMS | boerse | 69647580 |